Flatiron Health Announces Research to Be Presented at ASCO 2025
NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced 14 abstracts leveraging its high-quality real-world oncology data have been accepted for poster presentation and online publication at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. These studies exemplify Flatiron's commitment to advancing cancer research and align with this year's ASCO theme, 'Driving Knowledge to Action: Building a Better Future,' by delivering critical evidence to inform and improve patient care.
Our research accepted at this year's ASCO demonstrates our lasting commitment to deliver actionable evidence and improve care for every person with cancer.
Share
'AI and related technologies have enabled us to unlock data and insights from our entire network of over five million people with cancer, providing unprecedented scale, efficiency, and innovation for both real-world evidence generation and clinical trial execution,' said Stephanie Reisinger, Senior Vice President & General Manager, Real-World Evidence. 'Our research accepted at this year's ASCO demonstrates our lasting commitment to deliver actionable evidence and improve care for every person with cancer.'
Highlights include:
a poster presentation utilizing advanced machine learning models to identify a cohort of over 195,000 to complete the largest real-world study to date examining ctDNA testing in early stage breast cancer
an abstract assessing how often PSMA-PET scans were used among non-Latinx/Hispanic White, Black, and Latinx patients with metastatic prostate cancer
an abstract demonstrating the potential of a centralized, tech-enabled screening service to make clinical trial enrollment and more efficient, particularly in community oncology settings
Schedule a meeting with Flatiron Health at ASCO 2025, and learn more about our abstracts and events, including workshops and panels.
Follow Flatiron Health on X and LinkedIn for more updates from #ASCO25 and visit us in person at Booth #11131.
Partners: University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado School of Public Health
Erin Fidyk, Patrick Ward, Melissa Estevez, Konstantin Krismer, John Ritten, Anca Marinescu, Aaron B. Cohen
Breast Cancer—Local/Regional/Adjuvant
Poster board: 148
Abstract number: 555
Partners: Memorial Sloan Kettering Cancer Center, AstraZeneca
Dana Rathkopf, Danni Zhao, Lana Kovacevic, Jenna Collins, Eunice Hankinson, Helen Marshall, Aaron Springford, Simran Shokar, Helene von Bandemer, Weiyan Li
Genitourinary—Prostate, Testicular, and Penile
Poster board: 295
Abstract number: 5096
Impact of social determinants of health on mortality in diffuse large B-cell lymphoma (DLBCL) using real-world data Partners: Yale School of Medicine, University of Alabama at Birmingham, Fox Chase Cancer Center, University of Texas Southwestern Medical Center, University of Colorado at Anschutz
Maureen Canavan, Mengru Wang, Olive Mbah, Maneet Kaur, Michael J. Hall, Adeel Khan, Jessica McDermott, Madeline Schmitter, Anosheh Afghahi, Gaurav Goyal
Quality Care/Health Services Research
Poster board: 436
Abstract number: 11097
Partners: UCLA, AstraZeneca, Memorial Sloan Kettering Cancer Center, The University of Chicago
Jay Lee, Daniel Simmons, Tiernan Mulrooney, Jeremy Snider, Lana Natalija Kovacevic, Karen Schwed, Aditya Juloori
Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Poster board: 199
Abstract number: 8078
Molecular residual disease (MRD) in solid tumors Partners: Taylor Cancer Research Center, Exact Sciences, Case Comprehensive Cancer Center
Majd T. Ghanim, John Nemunaitis, Tara Marti, Abhishek Dabral, Katherine Diaz-MacInnis, Judith Frederick, Marla Kuleszynski, Yichen Lu, Amanda Rodriguez-Sullivan, Melanie Palomares, Natalie Salituro, Soma Subramaniam, Anthony Tate, Kathleen Turnbull, Neal J. Meropol
Therapeutics—Molecularly Targeted Agents and Tumor Biology
Poster board: 486b
Abstract number: TPS3186
Assessment of racial/ethnic inequities in uptake of Prostate Specific Membrane Antigen - Positron Emission Tomography (PSMA-PET) scans among patients with metastatic prostate cancer in the United States (US) Eunice A. Ochuonyo, Samantha Reiss, Patrick J. Ward, Brooke A. Jarrett, Olive Mbah, Prakirthi Yerram, Laura Rivera-Reyes, Sophia Miller, Kelly Magee, Lynn Rosario, Wendy Wittman, Cleo A. Ryals
Online publication only
Accrual of racially and ethnically underrepresented populations with multiple myeloma associated with centralized patient screening in a multicenter study Partners: University of Colorado, Johnson & Johnson, New York Cancer and Blood Specialists
Anosheh Afghahi, Daniel Sanchez, Yichen Lu, Richard M. Zuniga, Laura Heste, Dina Gifkins, Britney Beaulieu, Catharine Cipolla, Barry Leybovich, Debra Mitchell, Jeffrey Nan, Ebube Onwasigwe, Hemang Patel, Paul Salcuni, Chloe Salzman, Neal J. Meropol, Ashita S. Batavia
Online publication only
A retrospective real-world study of first-line PD-(L)1 inhibitor use in patients with metastatic non-small cell lung cancer (mNSCLC) Partner: Incyte
Kim Saverno, Siobhan Halloran, Mark Guinter, Kelly Magee, Michael Ondovik, J.E. Hamer-Maansson, Mark Cornfeld, Mihaela Munteanu
Online publication only
A retrospective cohort study of real-world clinical outcomes in patients with CLL/SLL previously treated with covalent BTK inhibitor (cBTKi) and BCL2 inhibitor (BCL2i) regimens Partners: Merck & Co, MSD UK, Mayo Clinic
Jennifer Prescott, Christina Parrinello, Ahmed Sawas, Enrico De Nigris, Jing Yang, Erik Bloomquist, Indu Shrivastava, Changxia Shao, Xinyue Liu, Mohammed Farooqui, Sameer A. Parikh
Online publication only
Management and outcomes of rash, peripheral neuropathy (PN), and hyperglycemia (HG) during first-line (1L) treatment (Tx) of locally advanced/metastatic urothelial cancer (la/mUC) in a real-world setting Partners: Cleveland Clinic, Merck KGaA, EMD Serono
Amanda Nizam, Mairead Kearney, Valerie Morris, Seyed Hamidreza Mahmoudpour, Carroline Lobo, Chiemeka Ike, Jason Hoffman, Ilian Iliev, Prakirthi Yerram, Mark Guinter
Online publication only
Concordance of response-based clinical trial and machine learning–generated real-world end points Partner: Genentech
Qianyi Zhang, Konstantin Krismer, Yichen Lu, Qianyu Yuan, Aaron Dolor, Auriane Blarre, Aaron B. Cohen, Tori Williams, Sophia Maund, Minu K. Srivastava, Kelly Magee
Online publication only
Partners: Pfizer, University of San Francisco Helen Diller Family Comprehensive Cancer Center, MD Anderson Cancer Center, Dana-Farber Cancer Institute, European Institute of Oncology IRCCS, University of Milano, UPMC Hillman Cancer Center
Hope S. Rugo, Rachel M. Layman, Filipa Lynce, Xianchen Liu, Benjamin Li, Lynn McRoy, Aaron B. Cohen, Melissa Estevez, Giuseppe Curigliano, Adam Brufsky
Online publication only
Unmet need in adults and adolescents and young adults (AYAs) with B-cell acute lymphoblastic leukemia (B-ALL) in the US following a second relapse Partners: Memorial Sloan Kettering Cancer Center, Stanford Cancer Center, AstraZeneca, Tampa General Hospital Cancer Institute, Knight Cancer Institute, MD Anderson Cancer Center
Mark B. Geyer, Michaela Liedtke, Vikram Shetty, Anthony Proli, Yazan K Barqawi, Jenna Collins, Nikesh N. Shah, Jessica T. Leonard, Joseph Elias Jabbour
Online publication only
About Flatiron
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients' real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
4 hours ago
- Miami Herald
Trump reveals group of ‘wealthy people' wants to buy TikTok in US
President Donald Trump said a group of 'very wealthy people' wants to buy the Chinese-owned TikTok social media app that is facing a ban in the United States. During an interview Friday with Maria Bartiromo that appeared Sunday on Fox News, Trump said, 'We have a buyer for TikTok, by the way,' declining to name the potential buyers. 'I'll tell you in about two weeks,' he added. The president said he believes Chinese President Xi Jinping 'will probably' approve the deal for U.S. ownership of the video service, which was founded in September 2016. President Joe Biden signed a law in 2024 requiring TikTok to be blocked in the United States unless its parent company, ByteDance, sells it to a non-Chinese company over concerns that sensitive user data could be acquired by the Chinese government. The U.S. Supreme Court voted unanimously on Jan. 17 that TikTok must be banned from U.S. app stores unless the company divested from the platform and sold to an American company by Jan. 19. Biden said he didn't want to intervene in the final days of his presidency, the app went dark around 10:30 p.m. ET on Jan. 18 and the app ceased to appear on Apple and Google's app stores. The 170 million U.S. users and around 1 million creators lost access to the app for at least one day of the 23 million new videos uploaded daily. Those using the app spend about an hour a day looking at some of the 23 million new clips uploaded daily, with teens using it for 2-3 hours a day, according to Exploding Topics. But the next day, the company restored service after Donald Trump said he would pause the deadline for 75 days when he was sworn in as president on Jan. 20, and signed an executive order to do so on his first day in office. He has since pushed off the deadline two more times, with it now delayed until Sept. 17. In April, the White House said it was close to a deal in which 50% of the app would be owned by an American company. Negotiations ended when Trump announced tariffs on goods coming from China to the United States. Trump proposed 134% tariffs on most goods but it has been scaled back to 30% for some items. During his first presidency, on Aug. 6, 2020, Trump signed an executive order 'action must be taken to address the threat posed by one mobile application in particular, TikTok' from China. Trump later credited TikTok with gaining more young voters in the 2024 election and seemed to soften on his stance. ByteDance has also been reluctant to turn over rights to the app's algorithm. It is the fifth-most social network with 1.6 billion users in the world behind Facebook, YouTube, Instagram and WhatsApp, according to Statista. In April, Adweek compiled a list of suitors for U.S. rights, including Applovin, Amazon, Oracle, Blackstone and Andreessen Horowitz. None confirmed negotiations to Addwek. 'It does not feel like these are serious bids for TikTok,' David Arslanian, managing director of Progress Partners, told Adweek. 'It is hard to imagine any of these companies, like Amazon and Oracle, successfully operating just a piece of TikTok.' Copyright 2025 UPI News Corporation. All Rights Reserved.
UPI
6 hours ago
- UPI
Trump reveals group of 'wealthy people' wants to buy TikTok in U.S.
1 of 2 | A group of "very wealthy people" wants to buy the Chinese-owned TikTok social media app that is facing a ban in the United States, President Donald Trump said. File photo by John Angelillo/UPI | License Photo June 29 (UPI) -- President Donald Trump said a group of "very wealthy people" wants to buy the Chinese-owned TikTok social media app that is facing a ban in the United States. During an interview Friday with Maria Bartiromo that appeared Sunday on Fox News, Trump said, "We have a buyer for TikTok, by the way," declining to name the potential buyers. "I'll tell you in about two weeks," he added. The president said he believes Chinese President Xi Jinping "will probably" approve the deal for U.S. ownership of the video service, which was founded in September 2016. President Joe Biden signed a law in 2024 requiring TikTok to be blocked in the United States unless its parent company, ByteDance, sold it to a non-Chinese company over concerns that sensitive user data could be acquired by the Chinese government. The U.S. Supreme Court voted unanimously on Jan. 17 that TikTok must be banned from U.S. app stores unless the company divested from the platform and sold to an American company by Jan. 19. Biden said he didn't want to intervene in the final days of his presidency, the app went dark around 10:30 p.m. ET on Jan. 18 and the app ceased to appear on Apple and Google's app stores. The 170 million U.S. users and around 1 million creators lost access to the app for at least one day of the 23 million new videos uploaded daily. Those using the app spend about an hour a day looking at some of the 23 million new clips uploaded daily, with teens using it for 2-3 hours a day, according to Exploding Topics. But the next day, the company restored service after Donald Trump said he would pause the deadline for 75 days when he was sworn in as president on Jan. 20, and signed an executive order to do so on his first day in office. He has since pushed off the deadline two more times, with it now delayed until Sept. 17. In April, the White House said it was close to a deal in which 50% of the app would be owned by an American company. Negotiations ended when Trump announced tariffs on goods coming from China to the United States. Trump proposed 134% tariffs on most goods but it has been scaled back to 30% for some items exempt. During his first presidency, on Aug. 6, 2020, Trump signed an executive order "action must be taken to address the threat posed by one mobile application in particular, TikTok" from China. Trump later credited TikTok with gaining more young voters in the 2024 election and seemed to soften on his stance. ByteDance has also been reluctant to turn over rights to the app's algorithm. It is the fifth-most social network with 1.6 billion users in the world behind Facebook, YouTube, Instagram and WhatsApp, according to Statistica. In April, Adweek compiled a list of suitors for U.S. rights, including Applovin, Amazon, Oracle, Blackstone and Andreessen Horowitz. None confirmed negotiations to Addwek. "It does not feel like these are serious bids for TikTok," David Arslanian, managing director of Progress Partners, told Adweek. "It is hard to imagine any of these companies, like Amazon and Oracle, successfully operating just a piece of TikTok."
Business Wire
7 hours ago
- Business Wire
Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will host a webcast and conference call on June 30, 2025, at 8:30 a.m. ET to discuss AUR200 Phase 1 study results. The link to the webcast is available here. To join the conference call, please dial 877-407-9170/+1 201-493-6756. Click here for participant International Toll-Free access numbers. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.
